#0423

Cell-free DNA analysis for precision medicine in metastatic castration-sensitive prostate cancer

M. Fujiwara¹, T. Sumiyoshi¹, K. Mizuno¹, T. Goto¹, T. Kobayashi¹, S. Akamatsu²

¹Kyoto university, Urology, Kyoto, Japan
²Nagoya university, Urology, Nagoya, Japan

Introduction:

The treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC) has expanded over the last decade, and rational biomarkers based on biological evidence are urgently required to enable optimal treatment for each individual patient and improve treatment outcomes. We aimed to develop a comprehensive genomic profiling assay using cell-free DNA (cfDNA) as a minimally invasive biomarker of mCSPC.

Material and methods:

Approximately 10ml blood samples were collected from 10 patients with mCSPC before systemic therapies, and the plasma and buffy coat were separated. cfDNA and leukocyte DNA were extracted from the plasma and buffy coat, respectively, and targeted DNA sequencing was performed using a capture panel of the exon regions of 88 prostate cancer-related genes. We used our established pipeline, the eVIDENCE algorithm, to detect somatic mutations in cfDNA, and the CNV kit was used for copy number analysis. The proportion of tumor-derived cfDNA, the circulating tumor DNA (ctDNA) fraction, was estimated using two approaches: the variant allele frequency of somatic mutations and deviation in the allele fraction of heterozygous germline single-nucleotide variations. We also compared the somatic mutation profiles between cfDNA and patient-matched tumor tissues.

Results:

Nine of the 10 (90%) cfDNA samples had a quantifiable ctDNA fraction (median = 29.07%, range = 5.64%–64.4%). The most common mutated genes were FOXA1 (44.4% of ctDNA-detected samples), TP53 (22.2%), SPOP (22.2%), and AR (11.1%). Of the 22 somatic mutations detected in tumor tissues, 10 (45.5%) were shared in patient-matched cfDNA. Fifteen somatic mutations were detected only in cfDNA, including mutations in AKT1 and BRAF.